First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL)

References

• Jain P, Aoki E, Keating M, et al. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017;28(7):1554–1559.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Galetto J, Okos A, et al. Prolymphocytic leukaemia of B and T cell type. Lancet. 1973;2(7823):232–234.
   PubMed Web of Science ®Google Scholar
• Matutes E, Garcia Talavera J, O'Brien M, et al. The morphological spectrum of T-prolymphocytic leukaemia. Br J Haematol. 1986;64(1):111–124.
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle V, Pomfret M, Matutes E, et al. Cytogenetic studies on prolymphocytic leukemia. II. T cell prolymphocytic leukemia. Blood. 1987;70:926–931.
   PubMed Web of Science ®Google Scholar
• Chan WC, Check IJ, Heffner LT, et al. Prolymphocytic leukemia of helper cell phenotype: report of a case and review of the scientific literature. Am J Clin Pathol. 1982;77 (5):643–647.
   PubMed Web of Science ®Google Scholar
• Zamkoff KW, Poiesz BJ, Ruscetti FW, et al. Functional diversity within the suppressor phenotype as defined by monoclonal antibody in T-cell prolymphocytic leukemia. Am J Hematol. 1984;16(4):409–417.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol. 1989;42(6):567–584.
   PubMedGoogle Scholar
• Swerdlow SC, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. revised 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2017.
   Google Scholar
• Bellanger D, Jacquemin V, Chopin M, et al. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia. 2014;28(2):417–419.
   PubMed Web of Science ®Google Scholar
• Bergmann AK, Schneppenheim S, Seifert M, et al. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2014;53(4):309–316.
   PubMed Web of Science ®Google Scholar
• Kiel MJ, Velusamy T, Rolland D, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014;124(9):1460–1472.
   PubMed Web of Science ®Google Scholar
• Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78.(12):3269–3274.
   PubMed Web of Science ®Google Scholar
• Mercieca J, Matutes E, Dearden C, et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. JCO. 1994;12(12):2588–2593.
   PubMed Web of Science ®Google Scholar
• Dearden CE, Khot A, Else M, et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011;118(22):5799–5802.
   PubMed Web of Science ®Google Scholar
• Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997;15(7):2667–2672.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Cazin B, Coutré S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. JCO. 2002;20(1):205–213.
   PubMed Web of Science ®Google Scholar
• Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98(6):1721–1726.
   PubMed Web of Science ®Google Scholar
• Wiktor-Jedrzejczak W, Dearden C, de Wreede L, et al. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia. 2012;26(5):972–976.
   PubMed Web of Science ®Google Scholar
• Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema DJ, et al. EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). Bone Marrow Transplant. 2019;54(9):1391–1398.
   PubMed Web of Science ®Google Scholar
• Boidol B, Kornauth C, van der Kouwe E, et al. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood. 2017;130(23):2499–2503.
   PubMed Web of Science ®Google Scholar
• Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58(9):1–17.
   PubMed Web of Science ®Google Scholar
• Herling CD, Abedpour N, Weiss J, et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018;9(1):727.
   PubMed Web of Science ®Google Scholar
• Pham LV, Huang S, Zhang H, et al. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res. 2018;24(16):3967–3980.
   PubMed Web of Science ®Google Scholar
• He L, Tang J, Andersson EI, et al. Patient-customized drug combination prediction and testing for T-cell prolymphocytic leukemia patients. Cancer Res. 2018;78(9):2407–2418.
   PubMed Web of Science ®Google Scholar
• Shi Z, Yu J, Shao H, et al. Exploring the molecular pathogenesis associated with T-cell prolymphocytic leukemia based on a comprehensive bioinformatics analysis. Oncol Lett. 2018;16:301–307.
   PubMed Web of Science ®Google Scholar
• Andersson EI, Pützer S, Yadav B, et al. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia. 2018;32(3):774–787.
   PubMed Web of Science ®Google Scholar
• Schrader A, Crispatzu G, Oberbeck S, et al. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018;9(1):697.
   PubMedGoogle Scholar